Product Overview
[Drug Name]
Trade Name: Weiduomei
English Name: Dosmalfate Tablets
Chinese Pinyin: DuoSiMaZhiPian
[Main Ingredient]
The main ingredient of this product is dosmalfate.
[Properties]
This product is a yellow tablet.
[Indications]
This product is used to treat gastric and duodenal ulcers.
[Dosage and Administration]
Oral administration, twice daily, 1.5g (three tablets) each time.
[Adverse Reactions]
A small number of patients may experience nausea and vomiting, abdominal pain, diarrhea, gastric distension, acid reflux, heartburn, belching, rash, and constipation.
[Contraindications]
Not yet known.
[Precautions]
It is best not to take this product orally with other medications for therapeutic purposes, as this product may affect the absorption and therapeutic efficacy of these medications (see Drug Interactions). Please read the instructions carefully and use according to your doctor's instructions.
[Use in Special Populations]
Precautions for children: Not yet known.
Precautions for pregnancy and lactation: Not yet known. Elderly Precautions: Not yet clear.
[Drug Interactions]
1. Proton pump inhibitors such as omeprazole and antacids such as aluminum hydroxide should be taken at least 30 minutes after dosimol. 2. Quinolone antibiotics such as ciprofloxacin and norfloxacin should be taken 2 to 6 hours before or 4 hours after dosimol, as this drug may cause them to form insoluble compounds. 3. The antifungal drug ketoconazole should be taken at least 2 hours before dosimol. 4. Digoxin should be taken at least 2 hours before dosimol, as it may reduce digoxin absorption through an unspecified mechanism of action. Quinidine should be taken at least 4 hours before dosimol, as this drug may reduce its absorption. Tetracycline should be taken 2 to 3 hours before dosimol. 5. This product may reduce the pharmacological effects of oral lipid-lowering drugs such as clofibrate, the anticoagulant warfarin, and the hypoglycemic drug tolbutamide. Avoid taking these drugs concurrently.
[Pharmacological Action]
Dosimar is a gastric mucosal protective drug, acting in a similar manner to sucralfate, acting directly on the gastric mucosa without any antisecretory effect. Dosimar forms a protective film covering the mucosal surface and simultaneously forms a pepsin complex to reduce damage. It also increases PGE2 concentration in gastric fluid.
[Pharmacokinetics]
Dosimar is virtually unabsorbed after oral administration in rats, with no detectable levels in the plasma or urine of administered animals. It is virtually completely recovered in the feces 12 hours after oral administration, with an excretion half-life of 5-6 hours. Human studies have also shown that after oral administration of dosimar, no significant levels of the acidic organic moiety of the dosimar structure were detected in any plasma sample using HPLC. Cumulative clearance of 8g of dosimar in urine was less than 0.04% 72 hours after oral administration, with a detection limit of 0.1μg/ml.
[Storage]
Store tightly closed in a cool, dark, dry place.
[Specifications]
0.5g
[Packaging]
Double-sided composite aluminum foil packaging, 18 tablets per box.
[Expiration Date]
24 months
[Approval Number]
National Medicine Standard H20052435
[Manufacturer]
Xiangbei Wellman Pharmaceutical Co., Ltd.
